Dr. Reddy's faces revenue slowdown post gRevlimid boost, but new investments and partnerships offer long-term growth ...

Key pharma stocks, including Granules India and Gland Pharma, have shown substantial recovery, with the Nifty Pharma index ...

Dr. Reddy's Laboratories Ltd has generally positive cash flows and an excellent current ratio of 2.58. Additionally, the ...

Mayur Maheshwari, CEO of UPSIDA, said the Bulk Drug Pharma Park would be important in reducing India's dependence on China ...

Dr. Reddy's Laboratories Ltd. closed 7.02% short of its 52-week high of 1,420.20 rupees, which the company achieved on August ...

The daily Elliott Wave analysis for Dr Reddy Laboratories highlights a bullish trend with current market action in an impulsive phase. Orange wave 3 is unfolding within a broader navy blue wave 1 ...

Discover the Dr Reddys Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a top-performing stock. Keep track of Dr Reddys's latest details, including: Last ...

Investors eye several stocks as the Reserve Bank of India is expected to announce a rate cut, potentially boosting the market ...

Stocks including Bajaj Finserv, IREDA, Coal India, Dr Reddy's Labs, Praj Industries, JSW Energy, SpiceJet, Ashoka Buildcon ...

HSBC upgraded Dr. Reddy’s Laboratories Limited (NYSE:RDY) from Buy to Hold, raising the price target to INR1,445 from ...

Fintel reports that on June 5, 2025, HSBC upgraded their outlook for Dr. Reddy's Laboratories Limited - Depositary Receipt () ...